Biotech


  • An illustration of an adeno-associated virus.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Emerging biotech

    Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup

    The biotech, which fell behind Sarepta in developing a Duchenne gene therapy, will merge with AavantiBio, a gene therapy startup run by a former Sarepta executive.

    By Sept. 30, 2022
  • This image depicts the podcast series page for TD2's BioPharma Dive Podcast series, "Evolution and Innovation in Oncology Therapeutics Development"
    Image attribution tooltip
    Anne Callahan/BioPharma Dive
    Sponsored by TD2 Precision Oncology

    [PODCAST] Evolution and Innovation in Oncology Therapeutics Development

    The “Evolution and Innovation in Oncology Therapeutics Development” podcast series explores the role of multi-biomarkers in precision oncology.

    By BioPharma's Dive studioID • Sept. 30, 2022
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • A photograph of Amylyx Pharmaceuticals cofounders Josh Cohen and Justin Klee.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    ALS drug development

    ALS drug approved by FDA in closely watched decision, marking win for patients, developer

    The drug, which will be sold as Relyvrio, showed modest benefits in function and survival in testing. It also became the latest test of the FDA's flexibility toward new therapies for neurological disorders.

    By Updated Sept. 30, 2022
  • A science lab with no workers
    Image attribution tooltip
    alvarez via Getty Images
    Emerging biotech

    Sudo joins a wave of startups taking aim at Bristol Myers’ new skin disease drug

    The startup, which emerged Wednesday with $37 million in funding, is the latest company trying to top Bristol Myers’ TYK2 inhibitor Sotyktu.

    By Sept. 28, 2022
  • Beta-Amyloid Plaques and Tau in the Brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.

    In surprise result, Alzheimer’s drug from Eisai, Biogen shows benefit in large trial

    The companies said the drug, called lecanemab, met all of its goals in the Phase 3 study. The data are a significant finding and provide stronger support for a much-debated hypothesis for treating Alzheimer’s.

    By Updated Sept. 27, 2022
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex given green light to seek US approval of CRISPR-based therapy

    The company and its development partner, CRISPR Therapeutics, will begin submitting a rolling application in November. The blood disease treatment is the first of its kind to near an FDA review. 

    By Sept. 27, 2022
  • Scribe Therapeutics lab photo
    Image attribution tooltip
    Courtesy of Scribe Therapeutics

    Sanofi partners with Scribe to gain gene editing tools for cell therapy work

    The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer cells for cancer treatment.

    By Sept. 27, 2022
  • A group of researchers and patients from a research lab at UC San Francisco pose with a large check.
    Image attribution tooltip
    Permission granted by Ethan Perlstein and Klein Lab at UCSF
    Q&A // Emerging biotech

    Perlara CEO Ethan Perlstein on reviving a biotech and building a ‘Y Combinator of rare diseases’

    The CEO resuscitated the sector’s first public benefit corporation during the pandemic, building an unusually transparent model for biotechs. Now, he’s spun out a startup and is planning for more.

    By Sept. 27, 2022
  • A photograph of Prime Medicine CEO Keith Gottesdiener
    Image attribution tooltip
    Permission granted by Prime Medicine
    Emerging biotech

    Prime Medicine becomes the next high-profile biotech to test IPO waters

    The startup, which launched last year with $315 million in funding and plans to advance a new form of gene editing, is one of the first big venture-backed biotechs in several months to seek an IPO.

    By Sept. 26, 2022
  • Red human heart drawing on blue background
    Image attribution tooltip
    Jolygon via Getty Images

    AstraZeneca gives up on Ionis’ RNA drug for heart disease

    The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing. 

    By Sept. 23, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Servier cuts ties with Allogene, ending complex CAR-T partnership

    The French drugmaker terminated a nearly decade-old deal that helped Allogene emerge as the sector's largest "off-the-shelf" cell therapy developer.

    By Sept. 22, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    GSK buys into Spero’s comeback plan

    The British drugmaker is investing in Spero Therapeutics and acquiring most of the rights to an oral antibiotic the FDA previously rejected, but could approve if it succeeds in a new Phase 3 trial.

    By Sept. 22, 2022
  • Illustration of a macrophage devouring a cancer cell.
    Image attribution tooltip
    Design Cells via Getty Images
    Emerging biotech

    Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street

    The deal results from a strategic review Sesen, formerly known as Eleven Biotherapeutics, undertook after the FDA rejected its top drug last year. 

    By Sept. 21, 2022
  • A photograph of Jan W. Thomsen and Peter Krogstrup Jeppesen, from the University of Copenhagen.
    Image attribution tooltip
    Courtesy of University of Copenhagen

    Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’

    The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences.

    By Sept. 21, 2022
  • A photograph of an empty laboratory.
    Image attribution tooltip
    gorodenkoff via Getty Images
    Emerging biotech

    Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch

    When the company debuted in March, it announced plans to hire 200 employees over two years. Now, it’s laid off nearly half its staff in a year when the biotech sector has experienced a sharp market downturn.

    By Sept. 19, 2022
  • A 3D illustration of human lungs.
    Image attribution tooltip
    yodiyim via Getty Images

    Theravance, flush with royalty cash, buys shares from GSK

    The planned transaction will further unwind the respiratory disease company’s relationship with GSK, which dates back two decades.

    By Sept. 19, 2022
  • A micrograph showing triglyceride fat accumulated inside liver cells.
    Image attribution tooltip
    Dr_Microbe via Getty Images

    Alnylam, Regeneron to advance NASH drug after early signs of potential

    A gene discovery four years ago led to a partnership between the companies, which plan to start a Phase 2 study later this year after encouraging early data. 

    By Sept. 15, 2022
  • A photo of the Nasdaq stock exchange
    Image attribution tooltip
    Nasdaq

    Third Harmonic boosts biotech with sector’s top IPO in four months

    The startup’s $185 million initial public offering is the largest for the sector since early May and potentially a sign of renewed investor interest in young biotechs.

    By Sept. 15, 2022
  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Emerging biotech

    Pharmas back a startup’s plan to make CAR-T cells inside the body

    Capstan Therapeutics was formed by pioneering CAR-T and messenger RNA researchers and has secured funding from five large drugmakers.

    By Sept. 14, 2022
  • A 3D illustration of cancer cells.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Emerging biotech

    MD Anderson launches new spinout to develop radiopharmaceuticals

    The joint venture with Radiopharm Theranostics is pursuing a field of research that’s seen a string of recent deals and investments by large drugmakers. 

    By Kristin Jensen • Sept. 14, 2022
  • An illustration of interleukin 17
    Image attribution tooltip
    vdvornyk via Getty Images
    Emerging biotech

    Acelyrin sets hopes high for arthritis drug with $300M fundraise

    The well-funded startup is planning Phase 3 trials for a drug it claims could be superior to top-selling medicines from Novartis and others.

    By Sept. 14, 2022
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images

    Rubius, a once high-flying biotech startup, lays off much of its staff

    The biotech will reduce staff by 75% and end development of two drugs, the latest setback for a company that was worth nearly $2 billion when it went public in 2018.

    By Sept. 13, 2022
  • Image attribution tooltip
    Danielle Ternes/BioPharma Dive

    BioMarin reports cancer case in hemophilia gene therapy trial

    The development comes three weeks after Roctavian was approved in Europe and ahead of a planned regulatory submission in the U.S. Drug regulators have not ordered a trial hold, however.

    By Sept. 13, 2022
  • Third Harmonic CEO Natalie Holles
    Image attribution tooltip
    Permission granted by Third Harmonic
    Emerging biotech

    Can biotech IPOs bounce back? Third Harmonic to test investor appetite with planned offering

    The startup is the first young drugmaker in more than four months to seek an IPO of at least $100 million, a once common occurrence that's become rare following this year's sector-wide correction.

    By Sept. 13, 2022
  • A person in an office uses a virtual reality headset to examine a 3D model on a computer screen.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics

    Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug

    The money will help fund development of a TYK2 inhibitor that Nimbus CEO Jeb Keiper claims is more selective than Bristol Myers’ Sotyktu.

    By Sept. 12, 2022